{"id":"flu-mel","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1790717","moleculeType":"Small molecule","molecularWeight":"1339.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Flu-Mel works by inhibiting the neuraminidase enzyme, which is essential for the release of new viral particles from infected cells. This mechanism of action helps to reduce the spread of the virus within the body, thereby alleviating symptoms and shortening the duration of illness.","oneSentence":"Flu-Mel is an antiviral medication that targets the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:47.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated influenza A and B in patients 2 weeks of age and older"}]},"trialDetails":[{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT03159702","phase":"PHASE2","title":"Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-12-08","conditions":"Hematological Malignancy, Multiple Myeloma","enrollment":43},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT04191187","phase":"PHASE2","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-12-06","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":34},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07078721","phase":"PHASE2","title":"Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-20","conditions":"Aplastic Anemia Idiopathic","enrollment":11},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT06125483","phase":"NA","title":"TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-11-01","conditions":"Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT05991908","phase":"PHASE3","title":"Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":222},{"nctId":"NCT06602323","phase":"PHASE2","title":"TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-01","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT06247917","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-03-03","conditions":"Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes","enrollment":59},{"nctId":"NCT06133556","phase":"PHASE2","title":"Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-24","conditions":"Acute Myeloid Leukemia","enrollment":237},{"nctId":"NCT04269811","phase":"PHASE2","title":"Flu-Bu-Mel Conditioning Regimen for Myeloid Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-15","conditions":"Relapse Rate After Allo-HSCT","enrollment":49},{"nctId":"NCT04897139","phase":"PHASE2","title":"Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-01-01","conditions":"Lymphoid Neoplasm","enrollment":23},{"nctId":"NCT01339910","phase":"PHASE3","title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-06","conditions":"Leukemia, Myelocytic, Acute","enrollment":272},{"nctId":"NCT01410344","phase":"PHASE2","title":"Allogeneic Transplant in HIV Patients (BMT CTN 0903)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":"Leukemia, Lymphoma, HIV","enrollment":20},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT02750254","phase":"PHASE1","title":"Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT04345549","phase":"NA","title":"Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak","status":"COMPLETED","sponsor":"Aarogyam UK","startDate":"2020-02-26","conditions":"Flu Like Symptom, Flu Like Illness","enrollment":18},{"nctId":"NCT02447055","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2015-12","conditions":"Multiple Myeloma, Myeloma-Multiple","enrollment":""},{"nctId":"NCT00800150","phase":"PHASE1","title":"Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2008-11","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":6},{"nctId":"NCT00189488","phase":"PHASE2","title":"Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-12","conditions":"Graft Versus Host Disease, Hematologic Malignancies","enrollment":155},{"nctId":"NCT00772811","phase":"PHASE2","title":"Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2001-07","conditions":"Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma","enrollment":38},{"nctId":"NCT00275678","phase":"PHASE3","title":"Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Blood Stem Cell Transplant","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludara-Alkaran"],"phase":"phase_2","status":"active","brandName":"Flu-Mel","genericName":"Flu-Mel","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flu-Mel is an antiviral medication that targets the influenza virus. Used for Treatment of uncomplicated influenza A and B in patients 2 weeks of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}